At the cutting edge of AAV capsid engineering

Cell & Gene Therapy Insights 2023; 9(4), 455–461

DOI: 10.18609/cgti.2023.066

Published: 31 May 2023
Eric Kelsic, Adrian Veres

Having emerged from the Harvard Lab of George Church, Dyno Therapeutics has set about tackling the key challenges and opportunities for the AAV gene therapy field through an AI-enabled approach to capsid engineering. David McCall, Senior Editor, BioInsights speaks to (pictured left to right) Dyno’s Eric Kelsic, CEO & co-founder and Adrian Veres, CSO & co-founder, about their vision and future plans to extend the reach of gene therapy.